Douglas Nixon

Weill Cornell Medical College

About Douglas Nixon

Dr. Douglas F. Nixon, M.D., Ph.D., graduated with a Bachelor of Science from University College London in 1981 with First Class Honors, and received his medical degree from Westminster Hospital Medical School, London in 1984. He then went on to train as a pathologist and clinical virologist at the University of Oxford and received his Master’s degree in 1991 and his PhD. in Immunology in 1992. During his time at Oxford, he made substantial contributions to the understanding of the newly emerged Human Immunodeficiency Virus (HIV). He spent the following  two years at a biotechnology company in New York working on HIV vaccine development, before joining the Aaron Diamond AIDS Research Centre at the Rockefeller University, first as a postdoctoral fellow, and subsequently as an assistant professor, to investigate how antiviral T cells function in pediatric HIV infection. In recognition of several important contributions to HIV/AIDS research he made while there, he was awarded the Elisabeth Glaser Scientist Award in 2000. That same year he joined the Gladstone Institute of Virology and Immunology in San Francisco as an Associate Professor. In 2006, he accepted the appointment of Professor of Medicine at the University of California, San Francisco (UCSF), and as Associate Chief of the Division of Experimental Medicine at UCSF. From 2013 -2018 he was recruited to the George Washington University as Chair and Walter G. Ross Professor (with tenure) of the Department of Microbiology, Immunology and Tropical Medicine. He is currently Professor of Immunology in Medicine at the Weill Cornell Medical College in New York City. A scientist and educator, he has actively pursued immunovirology research for more than 28 years, with his studies spanning from clinical research and human immunology, to basic virology, vaccine development and molecular biology. Among his accomplishments, Nixon has gained recognition for publishing the first identification of an HIV specific cytotoxic T cell (CTL) epitope. He has published more than 250 articles in peer-reviewed journals, including first-or-senior author publications in Nature, PNAS, Journal of Clinical Investigation, PLoS Pathogens, and holds several patents. He has served on multiple study section and grant review panels, and has mentored more than 50 students, postdocs and fellows. He is the past Chair of the NIH’s AIDS Vaccine Research Subcommittee. Dr. Nixon is currently the Principal Investigator of the NIH’s Martin Delaney collaboratory for HIV Cure Grant, “BELIEVE”.